Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACcomplisH
NCT04085523Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Jun 2020
- Primary completion
- Sep 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of navepegritide in achondroplasia (ACH) (5 arms), sponsored by Ascendis Pharma. Primary endpoint: Annualized Height Velocity at 52 weeks. Started Jun 2020; status: completed.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT04085523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085523.